{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-039878","form_type":"8-K","ticker":"ABSI","cik":"0001672688","company_name":"Absci Corp","filed_at":"2025-08-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.605263+00:00","generated_at":"2026-05-17T14:38:48.808354+00:00","sec_items":["2.02","8.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Absci Q2 net loss $30.6M; raises $64M in July extending runway to H1 2028; Almirall collaboration expands","bullets":["Net loss $30.6M in Q2 2025 (vs $24.8M in Q2 2024); revenue $0.6M (vs $1.3M).","Raised $64M ($50M public offering + $14M ATM) in July 2025; cash+investments $117.5M at June 30; runway into H1 2028.","Expanded Almirall collaboration: second target elected for dermatology; up to $650M in potential milestones across two programs.","ABS-101 Phase 1 interim data expected H2 2025; ABS-201 on track for Phase 1/2a start early 2026 with efficacy readout H2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-039878","json":"https://secwatch.observer/filing/0001628280-25-039878.json","markdown":"https://secwatch.observer/filing/0001628280-25-039878.md","text":"https://secwatch.observer/filing/0001628280-25-039878.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/0001628280-25-039878-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1672688/000162828025039878/absc-20250812.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T14:38:48.808354+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}